1. EARLY PET RESPONSE PREDICTS OUTCOME IN LARGE B‐CELL LYMPHOMA PATIENTS TREATED WITH CD19 CAR‐T. (17th June 2021) Authors: Cuadrado, M.; Menne, T.; Petrides, G.; Osborne, W.; Potter, V.; Benjamin, R.; Patten, P.; Yallop, D.; Sanderson, R.; Mulholland, N.; Kuhnl, A. Journal: Hematological oncology Issue: Volume 39(2021)Supplement 2 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PH-0329 Feasibility and outcome of bridging RT pre CAR-T in DLBCL in one centre with a wide referral network. (August 2021) Authors: Brady, J.; Vasiliadou, I.; Potter, V.; Benjamin, R.; Patten, P.; Cuadrado, M.; Evans, O.; Alexander, E.; Gillham, C.; Summers, J.; Ajithkumar, T.; Bates, A.; Sanderson, R.; Kuhnl, A.; Mikhaeel, N. Journal: Radiotherapy and oncology Issue: Volume 161(2021)supplement Page Start: S241 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. S141: ELICITING ANTI-TUMOR T CELL ACTIVITY IN CHRONIC LYMPHOCYTIC LEUKEMIA WITH BISPECIFIC ANTIBODY-BASED COMBINATION THERAPY. (23rd June 2022) Authors: Papazoglou, D.; Ysebaert, L.; Ioannou, N.; Apollonio, B.; Patten, P.; Herter, S.; Bacac, M.; Deutsch, A.; Klein, C.; Vardi, A.; Quillet-Mary, A.; Ramsay, A. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 42 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. S145: THE COMBINATION OF IBRUTINIB PLUS VENETOCLAX RESULTS IN A HIGH RATE OF MRD NEGATIVITY IN PREVIOUSLY UNTREATED CLL: THE RESULTS OF THE PLANNED INTERIM ANALYSIS OF THE PHASE III NCRI FLAIR TRIAL. (23rd June 2022) Authors: Hillmen, P.; Pitchford, A.; Bloor, A.; Pettitt, A.; Patten, P.; Forconi, F.; Schuh, A.; Fox, C.; Elmusharaf, N.; Gatto, S.; Kennedy, B.; Gribben, J.; Pemberton, N.; Sheehy, O.; Preston, G.; Howard, D.; Hockaday, A.; Cairns, D.; Jackson, S.; Greatorex, N. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 46 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. UMBRALISIB MONOTHERAPY DEMONSTRATES EFFICACY AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA: A MULTICENTER, OPEN‐LABEL, REGISTRATION DIRECTED PHASE 2 STUDY. (12th June 2019) Authors: Zinzani, P.; Samaniego, F.; Jurczak, W.; Lech‐Maranda, E.; Ghosh, N.; Anz, B.; Patten, P.; Reeves, J.; Leslie, L.A.; Smolewski, P.; Chavez, J.C.; Scarfo, L.; Derenzini, E.; Burke, J.M.; Sharman, J.; Kolibaba, K.; O'Connor, O.A.; Cheah, C.Y.; Miskin, H.P.; Sportelli, P. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 182 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗